Two Sigma Investments LP Boosts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Two Sigma Investments LP raised its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 78.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 751,894 shares of the company’s stock after purchasing an additional 331,417 shares during the period. Two Sigma Investments LP owned 1.54% of Cabaletta Bio worth $1,707,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of CABA. BIT Capital GmbH bought a new position in shares of Cabaletta Bio during the 4th quarter worth $431,000. Renaissance Technologies LLC purchased a new stake in Cabaletta Bio during the fourth quarter valued at about $522,000. Point72 Asset Management L.P. boosted its position in Cabaletta Bio by 89.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company’s stock worth $2,874,000 after purchasing an additional 598,607 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Cabaletta Bio by 10.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company’s stock worth $9,248,000 after purchasing an additional 400,282 shares during the period. Finally, Raiffeisen Bank International AG purchased a new position in shares of Cabaletta Bio in the fourth quarter worth about $493,000.

Cabaletta Bio Price Performance

Shares of NASDAQ:CABA opened at $2.06 on Tuesday. Cabaletta Bio, Inc. has a 1 year low of $0.99 and a 1 year high of $13.50. The company has a market cap of $104.53 million, a P/E ratio of -0.96 and a beta of 2.72. The stock’s fifty day moving average price is $1.39 and its 200-day moving average price is $2.03.

Cabaletta Bio (NASDAQ:CABA) last posted its earnings results on Wednesday, May 21st. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.04). On average, sell-side analysts anticipate that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on CABA. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Tuesday, April 1st. Wells Fargo & Company lowered their target price on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 1st. UBS Group cut their price target on shares of Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Guggenheim upped their price target on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Finally, Morgan Stanley decreased their target price on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cabaletta Bio currently has an average rating of “Buy” and a consensus price target of $20.33.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.